thalidomide has been researched along with Multiple Primary Neoplasms in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 9.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "Bortezomib was used as first-line induction therapy against both tumors and lenalidomide was used for maintenance." | 5.46 | Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| "The occurrence of multiple myeloma and chronic lymphocytic leukemia in the same patient is very uncommon." | 5.35 | Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. ( Schiffer, CA; Srinivasan, S, 2009) |
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 5.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "Bortezomib was used as first-line induction therapy against both tumors and lenalidomide was used for maintenance." | 1.46 | Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report. ( Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W, 2017) |
| "The occurrence of multiple myeloma and chronic lymphocytic leukemia in the same patient is very uncommon." | 1.35 | Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. ( Schiffer, CA; Srinivasan, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavarot, N | 1 |
| Lebbe, C | 1 |
| Thervet, E | 1 |
| Bouscary, D | 1 |
| Karras, A | 1 |
| Ise, M | 1 |
| Tsujimura, H | 1 |
| Sakai, C | 1 |
| Kumagai, K | 1 |
| Zuo, W | 1 |
| Zhu, X | 1 |
| Yang, J | 1 |
| Mei, Z | 1 |
| Deng, M | 1 |
| Lin, Q | 1 |
| Song, Y | 1 |
| Yin, Q | 1 |
| Srinivasan, S | 1 |
| Schiffer, CA | 1 |
| Fernández Salazar, LI | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Galante, I | 1 |
| Aller de la Fuente, R | 1 |
| González Hernández, JM | 1 |
| Gupta, A | 1 |
| Cohen, BH | 1 |
| Ruggieri, P | 1 |
| Packer, RJ | 1 |
| Phillips, PC | 1 |
| Saka, B | 1 |
| Erten, N | 1 |
| Oztürk, G | 1 |
| Yilmaz, C | 1 |
| Dogan, O | 1 |
| Buyukbabani, N | 1 |
| Besisik, SK | 1 |
| Calligaris, L | 1 |
| Marchetti, F | 1 |
| Ventura, A | 1 |
1 trial available for thalidomide and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Cohort Studies; Dermatologic Agents; Dose-Respons | 2003 |
7 other studies available for thalidomide and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidom | 2017 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; | 2014 |
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, | 2017 |
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; M | 2009 |
[Efficacy of thalidomide in digestive bleeding caused by angiodysplasias].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Cardiovascular Diseases; Cerebellar Neoplasms; Cerebe | 2009 |
Kappa light chain myeloma with initial cutaneous involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Drug Resistance, Neoplas | 2006 |
Intestinal plexiform neurofibromas.
Topics: Angiogenesis Inhibitors; Child; Diagnosis, Differential; Female; Humans; Ileal Neoplasms; Mesentery; | 2008 |